Benzinga · Jul 30, 2026
BGM Group Announces Chairman And Co-CEO Chen Xin Resigns, Effective July 30, 2026; Zhanchang Xin Appointed As New Chairman Of Board; Hong Li Named As Co-Chief Executive Officer
-SEC Filing
BG
NASDAQ · BGM
BGM Group Ltd.
Healthcare · Drug Manufacturers - Specialty & Generic
$0.28
Up+$0.00 (+0.71%)
Updated Sep 4, 2026, 8:54 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.18B
- P/E ratio
- -29.55
- Dividend yield
- 0.00%
- 52-week range
- $0.23 – $1.08
- Volume
- 42.23K
- Avg. volume
- 36.41K
Price performance
BGM price history
1M range · 21 trading sessions · Daily adjusted prices
BGM closed at $0.28 after 21 trading sessions, down 4.42% for the selected period.
- Last close
- $0.28
- Period change
- -4.42%
- Period low
- $0.25
- Period high
- $0.33
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 3, 2026 | $0.271 | $0.285 | $0.26 | $0.283 | 42.23K |
| Sep 2, 2026 | $0.273 | $0.2799 | $0.2603 | $0.2797 | 45.21K |
| Sep 1, 2026 | $0.265 | $0.2824 | $0.265 | $0.2729 | 32.19K |
| Aug 31, 2026 | $0.3177 | $0.3199 | $0.2601 | $0.2719 | 247.24K |
| Aug 28, 2026 | $0.2827 | $0.33 | $0.27 | $0.3275 | 894.12K |
| Aug 27, 2026 | $0.29 | $0.295 | $0.2801 | $0.2917 | 29.41K |
| Aug 26, 2026 | $0.261 | $0.2937 | $0.2551 | $0.2748 | 88.38K |
| Aug 25, 2026 | $0.2499 | $0.287 | $0.2309 | $0.265 | 104.34K |
| Aug 24, 2026 | $0.2668 | $0.2668 | $0.2287 | $0.2504 | 139.29K |
| Aug 21, 2026 | $0.2643 | $0.2699 | $0.2623 | $0.2623 | 12.3K |
| Aug 20, 2026 | $0.255 | $0.2783 | $0.2523 | $0.2633 | 34.21K |
| Aug 19, 2026 | $0.2652 | $0.30 | $0.2522 | $0.2802 | 83.76K |
| Aug 18, 2026 | $0.256 | $0.2899 | $0.2522 | $0.2881 | 102.79K |
| Aug 17, 2026 | $0.269 | $0.385 | $0.2601 | $0.2715 | 4.35M |
| Aug 14, 2026 | $0.304 | $0.31 | $0.2879 | $0.2912 | 39.4K |
| Aug 13, 2026 | $0.296 | $0.3003 | $0.286 | $0.2985 | 19.51K |
| Aug 12, 2026 | $0.2987 | $0.3185 | $0.28 | $0.2884 | 121.51K |
| Aug 11, 2026 | $0.30 | $0.30 | $0.29 | $0.291 | 40.35K |
| Aug 10, 2026 | $0.2995 | $0.3095 | $0.2958 | $0.2971 | 23.22K |
| Aug 7, 2026 | $0.31 | $0.31 | $0.2962 | $0.3004 | 20.1K |
| Aug 6, 2026 | $0.305 | $0.305 | $0.292 | $0.2961 | 12.46K |
Latest BGM news
The latest Smart Investors Daily articles mentioning BGM.
Stock researchCompany · Overview
BGM research
Overview
Company profile and research snapshot.
Company profile
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Feb 26, 2026
BGM Group Receives Nasdaq Noncompliance Notice, Gets 60 Days To Regain Compliance
BGM Group Ltd. (NASDAQ: BGM) (the "Company" or "BGM") announced on February 24, 2026, that it has received a notification (the "Notification") from the Listing Qualifications Department of The Nasdaq Stock Market
seekingalpha.com · Sep 24, 2025
BGM Group: I Think I Found An Undervalued Stock
32.7% of BGM's revenue is now from high-growth AI, pushing profit up 78%. Yet, the market still values it like a slow-moving API business. With β ≈ 0.04–0.05 and basically no leverage, you get CAPM ≈ 4.42% and WACC ≈ 4.41%, that math checks out. On my assumptions, the DCF lands at about $19.07 per share. Versus the current $8.93, that's roughly +113% upside—consistent with the "undervalued" call.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
